676 related articles for article (PubMed ID: 15728519)
1. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease.
Zhang Y; Joe G; Hexner E; Zhu J; Emerson SG
J Immunol; 2005 Mar; 174(5):3051-8. PubMed ID: 15728519
[TBL] [Abstract][Full Text] [Related]
2. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
Berger M; Wettstein PJ; Korngold R
Transplantation; 1994 Apr; 57(7):1095-102. PubMed ID: 7909395
[TBL] [Abstract][Full Text] [Related]
3. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
4. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
Jones SC; Friedman TM; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2004 Feb; 10(2):91-105. PubMed ID: 14750075
[TBL] [Abstract][Full Text] [Related]
5. Donor T cells lacking Fas ligand and perforin retain the capacity to induce severe GvHD in minor histocompatibility antigen mismatched bone-marrow transplantation recipients.
Marks L; Altman NH; Podack ER; Levy RB
Transplantation; 2004 Mar; 77(6):804-12. PubMed ID: 15077018
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
7. Central memory CD8+ T cells induce graft-versus-host disease and mediate graft-versus-leukemia.
Zheng H; Matte-Martone C; Jain D; McNiff J; Shlomchik WD
J Immunol; 2009 May; 182(10):5938-48. PubMed ID: 19414745
[TBL] [Abstract][Full Text] [Related]
8. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
[TBL] [Abstract][Full Text] [Related]
9. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
10. Graft-versus-host disease impairs vaccine responses through decreased CD4+ and CD8+ T cell proliferation and increased perforin-mediated CD8+ T cell apoptosis.
Capitini CM; Nasholm NM; Duncan BB; Guimond M; Fry TJ
J Immunol; 2013 Feb; 190(3):1351-9. PubMed ID: 23275602
[TBL] [Abstract][Full Text] [Related]
11. Host-reactive CD8+ memory stem cells in graft-versus-host disease.
Zhang Y; Joe G; Hexner E; Zhu J; Emerson SG
Nat Med; 2005 Dec; 11(12):1299-305. PubMed ID: 16288282
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic T cells treated with amotosalen prevent lethal cytomegalovirus disease without producing graft-versus-host disease following bone marrow transplantation.
Roback JD; Hossain MS; Lezhava L; Gorechlad JW; Alexander SA; Jaye DL; Mittelstaedt S; Talib S; Hearst JE; Hillyer CD; Waller EK
J Immunol; 2003 Dec; 171(11):6023-31. PubMed ID: 14634114
[TBL] [Abstract][Full Text] [Related]
13. APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease.
Zhang Y; Shlomchik WD; Joe G; Louboutin JP; Zhu J; Rivera A; Giannola D; Emerson SG
J Immunol; 2002 Dec; 169(12):7111-8. PubMed ID: 12471148
[TBL] [Abstract][Full Text] [Related]
14. Influence of the additional injection of host-type bone marrow on the immune tolerance of minor antigen-mismatched chimeras: possible involvement of double-negative (natural killer) T cells.
Sefrioui H; Billiau AD; Overbergh L; Rutgeerts O; Waer M
Transplantation; 1999 Nov; 68(10):1560-7. PubMed ID: 10589955
[TBL] [Abstract][Full Text] [Related]
15. An essential role for IFN-gamma in regulation of alloreactive CD8 T cells following allogeneic hematopoietic cell transplantation.
Asavaroengchai W; Wang H; Wang S; Wang L; Bronson R; Sykes M; Yang YG
Biol Blood Marrow Transplant; 2007 Jan; 13(1):46-55. PubMed ID: 17222752
[TBL] [Abstract][Full Text] [Related]
16. Identification of stem cell transcriptional programs normally expressed in embryonic and neural stem cells in alloreactive CD8+ T cells mediating graft-versus-host disease.
Kato K; Cui S; Kuick R; Mineishi S; Hexner E; Ferrara JL; Emerson SG; Zhang Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):751-71. PubMed ID: 20116439
[TBL] [Abstract][Full Text] [Related]
17. Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease.
Schultz KR; Bader S; Paquet J; Li W
Blood; 1995 Dec; 86(11):4344-52. PubMed ID: 7492796
[TBL] [Abstract][Full Text] [Related]
18. Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease.
Blaser BW; Roychowdhury S; Kim DJ; Schwind NR; Bhatt D; Yuan W; Kusewitt DF; Ferketich AK; Caligiuri MA; Guimond M
Blood; 2005 Jan; 105(2):894-901. PubMed ID: 15374888
[TBL] [Abstract][Full Text] [Related]
19. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
20. CD8+CD44(hi) but not CD4+CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHD.
Dutt S; Baker J; Kohrt HE; Kambham N; Sanyal M; Negrin RS; Strober S
Blood; 2011 Mar; 117(11):3230-9. PubMed ID: 21239702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
